INNOVATE Corp. VATE NYSE · Industrials · United States
$4.07 -3.55% -$0.15
Summary
40 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- It passes 8 of the 9 points of the Piotroski financial health test.
What to watch
- Revenue fell by 8.7% a year over the last 3 years.
- Out of every 100 USD of revenue, only 0.8 USD is left as net profit.
- Operating profit covers the interest on its debt only 1.3 times.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 4.5 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 12% a year over 5 years. Over the last 3 years it fell by 8.7% a year.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 84 USD
- Sales and administration 10 USD
- Taxes and other 4.6 USD
- Net profit 0.8 USD
Net profit, industry median (Engineering & Construction) 4.4 USD
Out of every 100 USD of revenue, 0.8 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 6.4 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
High, stretched- Yield
- 18.44%
- Paid out of profit
- 83%
The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Infrastructure Segment 98%
- Spectrum Segment 1.3%
- Life Sciences Segment (Pansend) 0.7%
By region
- UNITED STATES 98%
- All Other Geographic Locations 2.0%
Infrastructure Segment brings in 98% of revenue. Life Sciences Segment (Pansend) grew fastest, by 43% a year.
Segments in detail